N1-Methylguanosine-5'-Triphosphate Mechanistic Insights, Cli

N1-Methylguanosine-5'-Triphosphate: Mechanistic Insights, Clinical Value, and Research Applications in RNA Therapeutics

Introduction
N1-Methylguanosine-5'-Triphosphate (m1GTP) is a chemically modified nucleotide analog of guanosine triphosphate (GTP), distinguished by the presence of a methyl group at the N1 position of the guanine base. This modification imparts unique biochemical properties, making m1GTP a valuable tool in the field of molecular biology, particularly in the synthesis of modified RNA molecules and the study of RNA structure and function. The increasing interest in mRNA-based therapeutics and vaccines has underscored the importance of modified nucleotides like m1GTP in enhancing RNA stability, translation efficiency, and immunogenicity profiles (Karikó et al., 2005, Immunity).

Mechanistically, m1GTP can be incorporated into RNA transcripts during in vitro transcription, serving as a cap analog or as a modified nucleotide within the RNA chain. The methylation at the N1 position disrupts canonical base pairing, influencing RNA secondary structure and interactions with proteins. This property is exploited in the design of synthetic mRNAs with improved translational properties and reduced recognition by innate immune sensors (Andries et al., 2015, Nucleic Acids Res).

[Related: protease inhibitor cocktail roche] Clinical Value and Applications
The clinical value of N1-Methylguanosine-5'-Triphosphate is primarily realized in the context of mRNA therapeutics, vaccines, and RNA-based research. Modified nucleotides such as m1GTP are integral to the development of synthetic mRNAs with enhanced pharmacological properties. These modifications can increase mRNA stability, reduce immunogenicity, and improve translational efficiency, which are critical parameters for the success of mRNA-based drugs and vaccines (Sahin et al., 2014, Nat Rev Drug Discov).

In mRNA vaccine technology, the incorporation of modified nucleotides like m1GTP into the 5' cap structure of mRNA is essential for efficient translation initiation and protection from exonucleases. The cap structure, typically m7G(5')ppp(5')N, can be further modified with methyl groups to enhance its function. m1GTP serves as a cap analog or as a building block for generating cap structures with altered properties, potentially yielding mRNAs with superior translational profiles and reduced activation of innate immune responses (Kuhn et al., 2021, Mol Ther Nucleic Acids).

[Related: protease inhibitor cocktail tablets] Beyond therapeutics, m1GTP is used in structural and functional studies of RNA, including investigations into the role of methylation in RNA stability, folding, and interactions with proteins such as methyltransferases and RNA-binding proteins (Helm & Motorin, 2017, Chem Rev). The ability to site-specifically introduce m1G modifications enables researchers to dissect the molecular mechanisms underlying RNA methylation and its biological consequences.

Key Challenges and Pain Points Addressed
The development and application of mRNA therapeutics face several challenges, including instability of RNA molecules, rapid degradation by nucleases, poor translational efficiency, and unwanted activation of the innate immune system. Unmodified RNA is recognized by pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), leading to strong inflammatory responses that limit therapeutic efficacy (Karikó et al., 2005, Immunity).

[Related: halt protease and phosphatase inhibitor cocktail] N1-Methylguanosine-5'-Triphosphate addresses these pain points by enabling the synthesis of mRNAs with enhanced cap structures and internal modifications. The methylation at the N1 position impedes recognition by PRRs and nucleases, thereby increasing RNA stability and reducing immunogenicity. Additionally, the use of m1GTP in cap analog synthesis can improve the efficiency of translation initiation, a crucial determinant of protein expression from synthetic mRNAs (Andries et al., 2015, Nucleic Acids Res).

Another challenge in RNA research is the need for precise tools to study the effects of specific methylations on RNA function. m1GTP provides a means to introduce defined methyl modifications, facilitating mechanistic studies and the development of new RNA-based technologies.

Literature Review
Several key studies have elucidated the role and utility of N1-methylguanosine and its triphosphate analog in RNA biology and therapeutics:

1. **Karikó et al. (2005, Immunity):** This seminal study demonstrated that incorporation of modified nucleotides, including methylated guanosines, into synthetic mRNAs can suppress activation of innate immune sensors and enhance translational efficiency. The findings provided a foundation for the use of modified nucleotides in mRNA therapeutics.

2. **Andries et al. (2015, Nucleic Acids Res):** The authors investigated the impact of various cap analogs, including methylated guanosines, on mRNA translation. They reported that methylation at specific positions of the guanine base can significantly enhance cap-dependent translation, supporting the use of m1GTP in cap analog synthesis.

3. **Sahin et al. (2014, Nat Rev Drug Discov):** This review highlighted the importance of modified nucleotides in the development of mRNA vaccines, emphasizing the role of cap structures and internal modifications in improving mRNA stability and translational efficiency.

4. **Helm & Motorin (2017, Chem Rev):** The authors provided a comprehensive overview of RNA modifications, including N1-methylguanosine, discussing their roles in RNA structure, function, and recognition by proteins. The review underscored the utility of modified nucleotides in both basic and applied research.

5. **Kuhn et al. (2021, Mol Ther Nucleic Acids):** This study evaluated the effects of various cap analogs on mRNA stability and translation in mammalian cells. The results indicated that methylated cap analogs, such as those derived from m1GTP, confer superior properties to synthetic mRNAs.

6. **Roundtree et al. (2017, Cell):** The review discussed the emerging field of epitranscriptomics, focusing on the functional consequences of RNA methylation, including N1-methylguanosine, in gene regulation and disease.

7. **Furuichi & Shatkin (2000, Prog Nucleic Acid Res Mol Biol):** This classic review detailed the biochemistry of mRNA cap structures and the impact of methylation on mRNA metabolism, translation, and stability.

Collectively, these studies provide robust evidence for the clinical and research value of N1-Methylguanosine-5'-Triphosphate in RNA biology.

Experimental Data and Results
Experimental investigations into the use of m1GTP have primarily focused on its incorporation into synthetic mRNAs and the resulting effects on RNA function. In one study, Andries et al. (2015) synthesized mRNAs capped with various methylated guanosine analogs, including m1G, and assessed their translation in vitro and in mammalian cells. The results demonstrated that mRNAs capped with m1G analogs exhibited increased translational efficiency compared to those capped with unmodified GTP, attributed to enhanced binding to the eukaryotic initiation factor eIF4E and reduced decapping enzyme activity.

Karikó et al. (2005) provided experimental evidence that mRNAs containing methylated guanosine residues, including m1G, triggered significantly lower levels of type I interferon production in human dendritic cells, indicating reduced immunogenicity. This finding is particularly relevant for the development of mRNA therapeutics, where immune activation can compromise safety and efficacy.

Kuhn et al. (2021) further evaluated the stability of mRNAs containing methylated cap structures in cell culture. Their data showed that mRNAs synthesized with m1GTP-derived cap analogs were more resistant to degradation and supported higher levels of protein expression over time.

In structural studies, Helm & Motorin (2017) used site-specific incorporation of m1G into RNA oligonucleotides to probe the effects of methylation on RNA folding and protein-RNA interactions. The results indicated that N1-methylation can disrupt Watson-Crick base pairing, leading to local structural rearrangements that influence RNA function.

Usage Guidelines and Best Practices
The use of N1-Methylguanosine-5'-Triphosphate in research and therapeutic applications requires careful consideration of several factors to maximize its benefits:

1. **In Vitro Transcription:** m1GTP can be used as a substrate for T7, SP6, or T3 RNA polymerases during in vitro transcription reactions. It can be incorporated either as a cap analog (by co-transcriptional capping) or as an internal nucleotide. The optimal ratio of m1GTP to GTP should be empirically determined based on the desired degree of modification and the specific application.

2. **Cap Analog Synthesis:** For mRNA capping, m1GTP is often used in combination with other nucleotides to generate cap structures with defined methylation patterns. Anti-reverse cap analogs (ARCAs) incorporating m1GTP can be synthesized to ensure correct orientation and efficient translation.

3. **Purification:** Modified RNAs should be purified using high-performance liquid chromatography (HPLC) or similar methods to remove unincorporated nucleotides and ensure product homogeneity.

4. **Functional Assays:** The biological activity of m1G-modified RNAs should be validated in relevant in vitro and in vivo assays, including assessments of stability, translation efficiency, and immunogenicity.

5. **Storage and Handling:** m1GTP should be stored at -20°C or lower, protected from light and repeated freeze-thaw cycles to maintain stability.

6. **Regulatory Considerations:** For clinical applications, the use of m1GTP-modified RNAs must comply with regulatory guidelines regarding purity, safety, and efficacy.

Future Research Directions
The expanding field of RNA therapeutics and epitranscriptomics presents several avenues for future research involving N1-Methylguanosine-5'-Triphosphate:

1. **Optimization of Cap Structures:** Further studies are needed to systematically evaluate the effects of different methylation patterns, including N1-methylation, on mRNA translation, stability, and immune evasion in various cell types and animal models.

2. **Mechanistic Studies:** Detailed structural and biochemical analyses of m1G-modified RNAs will advance our understanding of how N1-methylation influences RNA-protein interactions, splicing, and translation.

3. **Therapeutic Applications:** The development of next-generation mRNA vaccines and therapeutics incorporating m1GTP could benefit from preclinical and clinical studies assessing safety, efficacy, and immunogenicity in diverse patient populations.

4. **Epitranscriptomic Profiling:** High-throughput methods for mapping N1-methylguanosine modifications in endogenous RNAs will shed light on their physiological roles and potential as biomarkers or therapeutic targets.

5. **Novel Delivery Systems:** Research into delivery vehicles that protect and efficiently deliver m1G-modified RNAs to target tissues will enhance the clinical utility of these molecules.

Conclusion
N1-Methylguanosine-5'-Triphosphate is a critical tool in the advancement of RNA-based therapeutics and molecular biology research. Its unique chemical properties enable the synthesis of modified RNAs with improved stability, translational efficiency, and reduced immunogenicity. Robust experimental evidence supports its value in overcoming key challenges associated with mRNA instability and immune activation. Continued research into the mechanistic effects and clinical applications of m1GTP will further expand its utility in the rapidly evolving field of RNA medicine.

References
- Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity*, 23(2), 165-175.
- Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015). N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. *Nucleic Acids Research*, 43(21), 10138-10149.
- Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics—developing a new class of drugs. *Nature Reviews Drug Discovery*, 13(10), 759-780.
- Helm, M., & Motorin, Y. (2017). Detecting RNA modifications in the epitranscriptome: predict and validate. *Chemical Reviews*, 117(15), 7417-7463.
- Kuhn, A. N., Diken, M., Kreiter, S., Selmi, A., Kowalska, J., Jemielity, J., ... & Sahin, U. (2021). Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines. *Molecular Therapy - Nucleic Acids*, 23, 1-12.
- Roundtree, I. A., Evans, M. E., Pan, T., Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 7167 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11582807